ProCE Banner Activity

CME

Highlights From the 2022 San Antonio Breast Cancer Symposium

Conference Coverage
Text Module

Read an expert analysis of important advances in breast cancer treatment presented at the 2022 San Antonio Breast Cancer Symposium.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 17, 2023

Expiration: March 16, 2024

No longer available for credit.

Share

Faculty

Sara A. Hurvitz

Sara A. Hurvitz, MD

Professor of Medicine
Director
Breast Cancer Clinical Trials Program
Division of Hematology/Oncology
David Geffen School of Medicine
Medical Director
Clinical Research Unit
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California

Joyce O'Shaughnessy

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Puma Biotechnology, Inc.

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with breast cancer.

Program Learning Goal

The goal of this activity is to improve learners’ knowledge of and, as appropriate, competence in applying data presented at SABCS to the treatment of patients with breast cancer.

Learning Objectives

After completing this activity, participants should be better able to:

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with early-stage or metastatic breast cancer

  • Identify subpopulations of patients with breast cancer most likely to benefit from a specific treatment plan based on prognostic or predictive markers

  • Evaluate new data on novel agents and therapeutic approaches for patients with breast cancer

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Sara Hurvitz, MD, FACP: researcher: Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, Cytomx, Daiichi-Sankyo, Dantari, Dignitana, Genentech/Roche, G1 Therapeutics, Gilead, GlaxoSmithKline, Greenwich Life Sciences, Immunomedics, Lilly, Macrogenics, Novartis, OBI Pharma, Orinove, Orum, Pfizer, Phoenix Molecular Designs, Pieris, PUMA, Radius, Samumed, Sanofi, Seattle genetics/Seagen, Zymeworks.

Joyce O'Shaughnessy, MD: consultant/advisor/speaker: AbbVie, Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, Athenex, Bayer, Bristol-Myers Squibb, Carrick Therapeutics, Celgene, Daiichi Sankyo, Eisai, G1 Therapeutics, Genentech, Genzyme, Gilead Sciences, GRAIL, Halozyme Therapeutics, Heron Therapeutics, Immunomedics, Ipsen Biopharmaceuticals, Lilly, Merck, Myriad, Nektar Therapeutics, Novartis, Ontada, Pfizer, Pharmacyclics, Pierre Fabre, Prime Oncology, Puma Biotechnology, Roche, Samsung Bioepis, Sandoz, Sanofi, Seagen, Syndax, Synthon, Taiho Oncology, Takeda, Theralink.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose. 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from March 16, 2023, through March 15, 2024:

  1. Create an account or Login at https://clinicaloptions.com/
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

 

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

 

Physician Continuing Medical Education

Credit Designation
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.